A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.
Completed · Phase 1 · NCT05858788
Conditions: Rheumatoid Arthritis
At a glance
- Research payments reported, 2025
- $117,255
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- Sanofi
- Tested
- SAR441566 (drug)
- Dates
- Started 2023-05-15; completion 2023-07-17
- Results posted
- Not yet
This is a cross-over, Phase 1, 3-treatment period single sequence study. The purpose of this study is to characterize pharmacokinetics (PK), safety, and tolerability of single ascending oral doses of SAR441566 in healthy male Japanese participants, 18-55 years of age.
From ClinicalTrials.gov, last updated 2025-09-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $117,255 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Parexel Intl Corp PArexel Intl Llc $117,255
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.